Share on LinkedInShare on LinkedIn

ARTICLE · 06 MAY 2021

Class Action Lawsuits: Looking South At Pharmaceutical Settlements

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

On April 16, 2021, the Ontario Superior Court of Justice released its decision in Casseres v. Takeda Pharmaceutical Company, 2021 ONSC 2846

CanadaLitigation, Mediation & Arbitration

On April 16, 2021, the Ontario Superior Court of Justice released its decision in Casseres v. Takeda Pharmaceutical Company, 2021 ONSC 2846, regarding the approval of a settlement of two pharmaceutical class action lawsuits. The class actions alleged that three diabetes medications caused bladder cancer and that class members were not warned of this risk.

The proposed settlement amount, achieved through mediation, was $25 million. The Court adjourned the initial settlement approval hearing after learning that actions in the United States in respect of the same medications were settled for a total of $2.4 billion. The Court noted that "using a per capita comparison, this would mean that a Canadian settlement in the range of $240 million would be more appropriate." The Court questioned how, in light of the U.S. settlements, the proposed settlement amount could be fair and reasonable. It adjourned the settlement approval hearing to allow class counsel to file

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from